See more : MedPacto, Inc. (235980.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of electroCore, Inc. (ECOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of electroCore, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Auroch Minerals Limited (AOU.AX) Income Statement Analysis – Financial Results
- Ambu A/S (AMBU-B.CO) Income Statement Analysis – Financial Results
- Verona Indah Pictures Tbk. (VERN.JK) Income Statement Analysis – Financial Results
- Meridian Energy Limited (MDDNF) Income Statement Analysis – Financial Results
- BASF India Limited (BASF.BO) Income Statement Analysis – Financial Results
electroCore, Inc. (ECOR)
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.03M | 8.59M | 5.45M | 3.50M | 2.39M | 992.95K | 811.46K | 254.14K |
| Cost of Revenue | 2.80M | 1.62M | 1.39M | 1.74M | 1.16M | 578.74K | 518.53K | 123.73K |
| Gross Profit | 13.23M | 6.98M | 4.07M | 1.76M | 1.23M | 414.21K | 292.93K | 130.41K |
| Gross Profit Ratio | 82.51% | 81.19% | 74.59% | 50.30% | 51.59% | 41.71% | 36.10% | 51.31% |
| Research & Development | 5.32M | 5.52M | 2.54M | 4.20M | 9.90M | 12.47M | 7.83M | 7.97M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.50M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.71M | 24.33M | 21.57M | 21.84M | 35.42M | 42.50M | 18.11M | 7.17M |
| Other Expenses | 0.00 | -6.00K | -8.30K | -17.80K | -12.00K | -344.91K | -4.89K | 7.17M |
| Operating Expenses | 32.03M | 29.85M | 24.11M | 26.04M | 45.32M | 54.97M | 25.94M | 15.14M |
| Cost & Expenses | 34.84M | 31.47M | 25.49M | 27.78M | 46.48M | 55.55M | 26.46M | 15.26M |
| Interest Income | 433.00K | 287.00K | 10.70K | 84.30K | 970.59K | 1.01M | 99.03K | 0.00 |
| Interest Expense | 0.00 | 287.00K | 0.00 | 8.34K | 0.00 | 0.00 | 7.12M | 771.25K |
| Depreciation & Amortization | 1.03M | 596.00K | 436.62K | 489.47K | 307.36K | 66.66K | 32.31K | 53.43K |
| EBITDA | -17.76M | -22.33M | -19.66M | -24.18M | -43.98M | -54.49M | -28.87M | -14.96M |
| EBITDA Ratio | -110.79% | -266.22% | -403.85% | -681.37% | -1,761.26% | -5,420.74% | -3,144.73% | -5,885.31% |
| Operating Income | -18.81M | -22.87M | -20.04M | -24.28M | -44.09M | -54.55M | -25.64M | -15.01M |
| Operating Income Ratio | -117.31% | -266.22% | -367.68% | -694.66% | -1,844.81% | -5,494.07% | -3,160.31% | -5,906.33% |
| Total Other Income/Expenses | -215.00K | 281.00K | 1.97M | -398.04K | -1.04M | -1.21M | -10.38M | -771.25K |
| Income Before Tax | -19.02M | -22.59M | -18.07M | -24.68M | -45.13M | -55.76M | -36.03M | -15.78M |
| Income Before Tax Ratio | -118.65% | -262.95% | -331.47% | -706.05% | -1,888.24% | -5,615.88% | -4,440.01% | -6,209.81% |
| Income Tax Expense | -186.00K | -431.00K | -851.20K | -1.17M | 18.00K | 2.43K | 6.88M | -44.15K |
| Net Income | -18.83M | -22.16M | -17.22M | -23.51M | -45.15M | -55.82M | -35.79M | -15.74M |
| Net Income Ratio | -117.49% | -257.94% | -315.86% | -672.55% | -1,889.00% | -5,621.66% | -4,410.88% | -6,192.44% |
| EPS | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| EPS Diluted | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| Weighted Avg Shares Out | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
electroCore Completes Sale of New Jersey Tax Benefits
ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority's Technology...
electroCore Announces Reverse Stock Split
ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15. The...
electroCore Announces Issuance of Two New U.S. Patents
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS)...
gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium.
5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%
Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health...
electroCore, Inc. (ECOR) Q3 2022 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer...
electroCore Announces Third Quarter 2022 Financial Results
Third quarter 2022 revenue grew 33% over third quarter 2021
electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
ROCKAWAY, N.J. and CHARLOTTE, N.C.
electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.
Source: https://incomestatements.info
Category: Stock Reports